ClinicalTrials.gg
Sign In

Drug

Mocertatug rezetecan clinical trials

Also written HS-20089.

studies test it
12
open now
12
in phase 3
7
first study started
2010

Keep track of what changes. Save the mocertatug rezetecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Mocertatug rezetecan
5

Development codes

HS-20089
2
GSK 5733584
1

Combined with it in one product

HS-20089+Bevacizumab
1
GSK 5733584 + Dostarlimab
1
HS-10502 + HS-20089
1

Studies by the year they started

12 studies that test it; most in 2026 (6)

Studies that test mocertatug rezetecan, by start year
YearStudies
20101
20221
20231
20241
20252
20266

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
2
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it.

Ovarian Neoplasms
6
Endometrial Neoplasms
2
Neoplasms
2
Triple Negative Breast Neoplasms
1

Who runs them

Industry 11 · Other 1

GlaxoSmithKline (6) · Hansoh BioMedical R&D Company (3) · QuantumLeap Healthcare Collaborative (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Shanghai Hansoh Biomedical Co., Ltd (1)

Often tested with

Tested in the same studies.

Bevacizumab (2) · Trebananib (1) · Trastuzumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Pexidartinib (1) · Talazoparib (1)

Studies

Open first, then newest update. How each study uses mocertatug rezetecan is read from its arms, and is right about nine times in ten.

Testing it · 12

Given in every arm · 1 — mocertatug rezetecan is usual care beside what is tested

Codes

What other systems call mocertatug rezetecan · ClinicalTrials.gg INT015483

  • UNII (FDA) 7K6VKK6DP4MOCERTATUG REZETECANOne source FDA
  • NCI Thesaurus C210991Mocertatug RezetecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.